The Life Sciences team advised Scholar Rock Holding Corporation on the completion of its registered direct offering of 16,326,530 shares of common stock, Pre-funded Warrants to purchase up to 25,510,205 shares of common stock and Common Warrants to purchase up to 10,459,181 shares of common stock to the public at $4.90 per share of common stock and accompanying Common Warrant and $4.8999 per Pre-funded Warrant and accompanying Common Warrant. The accompanying warrants are immediately exercisable, expire on December 31, 2025 and have an exercise price of $7.35 per share. Through the registered direct offering, Scholar Rock raised aggregate gross proceeds of $205 million before deducting underwriting discounts and estimated offering expenses.
Based in Cambridge, Massachusetts, Scholar Rock is a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role.
The Goodwin team was led by partners Laurie Burlingame and Kingsley Taft and associates Jesse Fishman, Chris Guerin, Cameron Hagen and Sean Cheatle, and included partners Susan Lee and Ettore Santucci and associate Sarah Wicks.
For additional details on the offering, which closed on Wednesday, June 22, 2022, please read the press release.